Register
Forgot your password?

Cardiotoxicity of chemotherapy: current problems and challenges of modern oncology

Authors: Khidirova L.D., Andreeva M.A., Roman G.N.

Company: 1 Novosibirsk State Medical University, Novosibirsk, Russian Federation
2 Novosibirsk Regional Clinical Cardiology Dispensary, Novosibirsk, Russian Federation

For correspondence:  Sign in or register.

Type:  Reviews


DOI: https://doi.org/10.24022/1997-3187-2024-18S-S64-S71

For citation: Khidirova L.D., Andreeva M.A., Roman G.N. Cardiotoxicity of chemotherapy: current problems and challenges of modern oncology. Creative Cardiology. 2024; 18 (Special Issue): S64–S71 (in Russ.). DOI: 10.24022/1997-3187-2024-18S-S64-S71

Received / Accepted:  02.12.2024 / 12.12.2024

Keywords: cardiotoxicity chemotherapy oncology cardiomyopathy anthracyclines HER2-targeted therapy taxanes alkylating agents VEGF-mediated angiogenesis inhibitors checkpoint inhibitor therapy

Download
Full text:  

 

Abstract

Chemotherapy remains a key method of treating malignant neoplasms, but its cardiotoxicity raises significant concerns due to the risk of developing serious cardiovascular complications such as coronary heart disease, cardiomyopathy, heart failure, arrhythmias, myocarditis, pericarditis, hypertension and sudden cardiac death. This review, based on the analysis of studies from the PubMed, Embase, Web of Science and e-Library databases, is devoted to the pathogenetic mechanisms of cardiotoxicity, clinical features and modern diagnostic criteria related to the use of chemotherapy drugs in oncology. Despite the fact that anthracyclines are traditionally considered the main agents causing cardiotoxicity, drugs of other groups are equally important. Modern diagnostic approaches demonstrate significant diversity, which makes it difficult to uniformly assess the condition of patients. The results of the analysis revealed the need for further study of the pathogenesis of cardiotoxicity and the development of clear diagnostic standards to ensure timely intervention and prevention of complications.

References

  1. Santos V.M.D, Santos L.A.M.D. Cardiotoxicity in chemotherapeutic agents. Russian Open Medical Journal. 2021; 10 (1). DOI: 10.15275/ rusomj.2021.0106
  2. Tsyrenov D.D., Tsyrenova E.B., Sysoev S.U. Cardiooncology: current status of the issue, interdisciplinary interaction. Bone and Soft Tissue Sarcomas Tumors of the Skin. 2022; 14 (4): 22–25 (in Russ.). DOI: 10.17650/2782-3687-2022-14-4-22-25
  3. Kushnareva E.A., Astafurova O.E., Zorina E.Yu, Moiseeva O.M. Reasons for and time to seeking healthcare in cardiac clinics by women with a history of successfully treated breast cancer. Patologiya Krovoobrashcheniya I Kardiokhirurgiya. 2023; 27 (2): 19–26 (in Russ.). DOI: 10.21688/1681-3472-2023-2-19-26
  4. Gumerova K.S., Sakhautdinova G.M., Polyakova I.M. Antitumour drug induced cardiovascular toxicity and current tumour treatment methods. Creative Surgery and Oncology. 2020; 9 (4): 285–292 (in Russ.). DOI: 10.24060/2076-3093-2019-9-4-285-292
  5. Chazova I.E., Ageev F.T., Aksenova A.V., Vitsenya M.V., Gilyarov M.Yu., Martynyuk T.V. et al. Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). Eurasian Heart Journal. 2022; (1): 6–79 (in Russ.). DOI: 10.38109/2225-1685-2022-1-6-79
  6. Cozma A., Sporis N.D., Lazar A.L., Buruyana A., Ganea A.M., Malinescu T.V. et al. Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review. Int. J. Molecular Sci. 2022; 23 (18): 10948. DOI: 10.3390/ijms231810948
  7. Kozjavin N.A., Mureyko E.A., Nikiforov V.S., Beljaev A.M. Anthracycline-induced cardiomyopathy in the long-term period after chemotherapy: clinical case. CardioSomatics. 2023; 13 (3): 176–180 (in Russ.). DOI: 10.17816/cs133645
  8. Khidirova L.D., Latsvieva A.E., Vederin A.V. Cardiotoxicity mechanisms of antitumor therapy with immune checkpoint inhibitors: new achievements. Rational Pharmacotherapy in Cardiology. 2024; 20 (2): 265–274 (in Russ.). DOI: 10.20996/1819-6446-2024-3022
  9. Kushnareva E.A., Moiseeva O.M. Immune checkpoint inhibitor myocarditis: a systematic case study. Russian Journal of Cardiology. 2020; 25 (11): 3910 (in Russ.) DOI: 10.15829/29/1560-4071-2020-3910
  10. Wu B.B., Leung K.T., Poon E.N.Y. Mitochondrial-targeted therapy for doxorubicin-induced cardiotoxicity. Int. J. Molecular Sci. 2022; 23 (3): 1912. DOI: 10.3390/ijms23031912
  11. Kozyavin N.A., Mureyko E.A., Nikiforov V.S. Management of arterial hypertension during therapy with antiangiogenic drugs in metastatic renal cell carcinoma. Medical Alphabet. 2023; (17): 58–64 (in Russ.). DOI: 10.33667/2078-5631-2023-17-58-64
  12. Kong C.Y., Guo Z., Song P., Zhang S., Yuan Yu.., Teng T. et al. Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: oxidative stress and cell death. Int. J. Biol. Sci. 2022; 18 (2): 760–770. DOI: 10.7150/ijbs.65258
  13. Radulescu L.M., Radulescu D., Ciuleanu T.E. Cardiotoxicity associated with chemotherapy used in gastrointestinal tumours. Medicina. 2021; 57 (8): 806. DOI: 10.3390/medicina57080806
  14. Vasyuk Yu.A., Shupenina E.Y., Novosel E.O., Agapov I.S. Heart rhythm and conduction disorders as manifestations of cardiotoxicity of anticancer treatment: myth or reality? The Siberian Journal of Clinical and Experimental Medicine. 2020; 35 (1): 13–21 (in Russ.). DOI: 10.29001/2073-8552-2020-35-1-13-21
  15. Emelina E.I., Gendlin G.E., Nikitin I.G., Dmitrieva E.A., Nikitin E.A., Ptushkin V.V. Rhythm and conduction disorders in patients receiving ibrutinib. Clinical Oncohematology. 2019; 12 (2): 120–130 (in Russ.). DOI: 10.21320/2500-2139-2019-12-2-220-230
  16. Patel R.P., Parikh R., Gunturu K.S., Chappie M., Bruzzone M., Ponde N. et al. Cardiotoxicity of immune checkpoint inhibitors. Curr. Oncol. Reports. 2021; 23 (7). DOI: 10.1007/s11912-021-01070-6
  17. Fashafsha Z.A., Chomakhidze P.Sh., Mesitskaya D.F., Suvorov A.Yu., Sekacheva M.I., Poddubskaya E.V. et al. Early echocardiographic alterations in cancer patients during chemotherapy. Russian Journal of Cardiology. 2022; 27 (11): 5093-5093 (in Russ.). DOI: 10.15829/1560-4071-2022-5093
  18. Watutin N.T., El khatib M.A.I. Characterization of morphofunctional parameters of the heart and biomarkers of myocardial damage in patients of different age groups on the background of therapy with anthracycline antibiotics. Current Problems Of Medicine. 2021; 44 (4): 404–416 (in Russ.). DOI: 10.52575/2687-0940-2021-44-4-404-416
  19. Belenkov Yu.N., Ilgisonis I.S., Kirichenko Yu.Yu., Murtuzaliev Sh.M. Cardio-oncology today: digest of the first European clinical guidelines (2022). Kardiologiia. 2023; 63 (7): 3–15 (in Russ.). DOI:10.18087/cardio.2023.7.n2445
  20. Kanorskii S.G., Pavlovets V.P. Codiotoxicity of anthraciclines and the possibilities of its correction. South Russian Journal of Therapeutic Practice. 2023; 4 (3): 7–14 (in Russ.). DOI: 10.21886/2712-8156-2023-4-3-7-14
  21. Buziashvili Y.I., Asymbekova E.U., Tugeeva E.F., Akildzhonov F.R. The role of artificial intelligence in cardio-oncology: present and future: A review. Consilium Medicum. 2023; 25 (1): 29–33 (in Russ.). DOI: 10.26442/20751753.2023.1.202095
  22. Emelina E.I., Gendlin G.E., Nikitin I.G. Cardio-oncology and Oncohematology: examination algorithms, prophylactic and treatment of cardiotoxicity, Trends in Rehabilitation. Clinical Oncohematology. 2021; 14 (2): 239–261 (in Russ.). DOI: 10.21320/2500-2139-2021-14-2-239-261

About Authors

  • Lyudmila D. Khidirova, Dr. Med. Sci., Professor, Cardiologist; ORCID
  • Marina A. Andreeva, Student; ORCID
  • Ganna N. Roman, Resident Physician; ORCID

Chief Editor

Elena Z. Golukhova, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by